Home » Stocks » Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. (SYRS)

Stock Price: $10.85 USD 0.48 (4.63%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 495.77M
Revenue (ttm) 3.91M
Net Income (ttm) -76.20M
Shares Out 45.69M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $10.85
Previous Close $10.37
Change ($) 0.48
Change (%) 4.63%
Day's Open 10.30
Day's Range 10.12 - 10.89
Day's Volume 196,981
52-Week Range 4.26 - 12.75

More Stats

Market Cap 495.77M
Enterprise Value 419.80M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.69M
Float 38.25M
EPS (basic) -1.79
EPS (diluted) -1.78
FCF / Share -1.22
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.19M
Short Ratio 7.28
Short % of Float 11.92%
Beta 1.62
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 126.89
PB Ratio 6.02
Revenue 3.91M
Operating Income -78.11M
Net Income -76.20M
Free Cash Flow -53.41M
Net Cash 75.97M
Net Cash / Share 1.66
Gross Margin 50.73%
Operating Margin -1,999.13%
Profit Margin -1,950.40%
FCF Margin -1,367.14%
ROA -39.08%
ROE -108.43%
ROIC -88.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(18.53% upside)
Current: $10.85
Target: 12.86
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-3.32%86.19%247.32%0%--
Gross Profit1.982.051.100.320.32-
Operating Income-77.74-64.30-54.69-47.96-29.82-13.44
Net Income-75.44-62.28-54.01-47.74-29.82-13.43
Shares Outstanding40.2232.6625.4112.701.981.53
Earnings Per Share-1.88-1.91-2.13-4.05-17.55-10.26
Operating Cash Flow-60.25-40.32-44.73-40.54-23.03-11.97
Capital Expenditures-12.53-1.38-0.82-2.32-1.18-0.20
Free Cash Flow-72.78-41.69-45.55-42.86-24.21-12.17
Cash & Equivalents91.7110072.2484.0836.3960.46
Total Debt25.920.
Net Cash / Debt65.7910072.1983.8636.0560.46
Book Value79.1878.5965.3280.60-47.96-21.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Syros Pharmaceuticals, Inc.
Country United States
Employees 83
CEO Nancy A. Simonian

Stock Information

Ticker Symbol SYRS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SYRS
IPO Date June 30, 2016


Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.